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Abstract
Objectives—Little is known about erythropoiesis-stimulating agents (ESAs) utilization among
lupus nephritis (LN) patients with incipient ESRD. We aimed to identify sociodemographic and
clinical factors associated with ESA use among incident LN ESRD patients.
Methods—Among all individuals age ≥18 with incident ESRD from 1995-2008 in the U.S.
Renal Data System (USRDS), we identified those with systemic lupus erythematosus (ICD-9 code
710.0) as the cause of ESRD. ESA use at ESRD onset was ascertained from the Medical Evidence
Report. Year of onset, age, sex, race/ethnicity, medical insurance, employment status, residential
region, clinical factors and comorbidities were considered potentially associated with ESA use in
multivariable-adjusted logistic regression analyses.
Results—We identified 12,533 individuals with incident LN ESRD (1% of entire population).
Of those, 4,288 (34%) received an ESA preceding ESRD. In multivariable-adjusted models, ESA
users had higher serum albumin and hemoglobin concentrations, were more likely to be women,
and to live in the Northeast. Conversely, Medicaid beneficiaries, the uninsured, unemployed,
African Americans, Hispanics, and those with IV drug use, congestive heart failure and obesity
had lower ESA use.
Conclusion—Among all U.S. patients and those with LN who developed ESRD, approximately
one third received ESAs. Patient sex, race, age, medical insurance, residential region and clinical
factors were significantly associated with ESA therapy. While there are no guidelines for ESA use
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in LN patients approaching ESRD, there has been wide sociodemographic variation, raising
questions about ESA prescription practices.
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Race; Ethnicity; Access to care; Sociodemographic
Introduction
Systemic lupus erythematosus (SLE) is an autoimmune disease of unknown etiology which
can cause multiorgan system damage and which disproportionately affects women and non-
Caucasian minorities. Up to 60% of SLE patients develop renal disease, lupus nephritis
(LN), and of these, approximately one fifth progress to end-stage renal disease (ESRD)
within 10 years [1,2]. As LN progresses, anemia is a common clinical problem. The use of
recombinant human erythropoiesis-stimulating agents (ESAs) for patients with chronic
kidney disease-associated anemia, first approved in 1989, has resulted in substantial clinical
benefits, including correction of anemia and improvement of symptoms such as fatigue,
decreased cognition and mental acuity, as well as improved quality of life, reduction of the
need for ongoing transfusions and iron supplements [3,4].
Among patients with LN in the U.S., African Americans, Hispanics, and patients in lower
socioeconomic classes have poorer prognoses [5]. These sociodemographic groups have also
been found to have more severe laboratory abnormalities (higher serum creatinine and lower
hematocrit levels) at the start of renal replacement therapy for ESRD of all causes [6].
Differential access to healthcare, such as primary preventive care, specialized physician
care, indicated medications and procedures, may contribute to observed sociodemographic
disparities in the development of LN ESRD and death. Among patients with LN-associated
ESRD, we have found that being young, White, employed, and living in an area of higher
socioeconomic class, were all strongly associated with increased chances of receiving a
renal transplant or peritoneal dialysis, as opposed to hemodialysis, as the initial renal
replacement therapy [5].
Patterns of ESA use for anemia among patients with LN-associated chronic kidney disease,
however, have never been examined. It is not known what proportion of LN patients receive
ESAs, nor which clinical and sociodemographic factors influence prescribing patterns. In the
present study, we investigated sociodemographic and clinical factors associated with use of
ESAs prior to renal replacement therapy for LN-associated ESRD in the U.S from
1995-2008.
Methods
Study population
The US Renal Data System (USRDS) is the U.S. national registry of patients with ESRD
[6]. We conducted a cross-sectional study that included all individuals age ≥ 18 with
incident ESRD secondary to systemic lupus erythematosus (ICD-9 code 710.0) from 1995 to
2008 in the USRDS. The Partners’ Healthcare Institutional Review Board reviewed this
study protocol and granted it a waiver as human subjects’ exempt research. A data use
agreement with USRDS was obtained for this study.
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Data collection
Use of ESAs at the time of renal replacement therapy initiation (dialysis or kidney
transplantation) was ascertained from the Medical Evidence Report (CMS form 2728),
completed by attending nephrologists and required by the U.S. government. The Medical
Evidence Report contains patient demographic information, including age at the time of
initiation of renal replacement therapy, sex, race (White, African American, Asian, or
American Indian), Hispanic ethnicity, and state and zip code of residence. It also records the
individual’s body mass index (BMI; categorized as underweight<18, normal>18 to 25, and
obese>25 kg/m2), and diagnosed comorbidities, including hypertension, diabetes mellitus,
coronary artery disease (CAD), peripheral vascular disease (PVD), chronic obstructive
pulmonary disease, cancer, cerebrovascular accidents (CVA), congestive heart failure
(CHF), previous smoking history, and intravenous drug abuse. Certain laboratory
measurements, including serum levels of estimated glomerular filtration rate (eGFR),
albumin and hemoglobin, are reported. The type of medical insurance prior to the onset of
ESRD is also recorded (private, Medicaid, Medicare, other, or none).
Statistical analyses
We examined trends in the use of ESAs among those with incident LN-associated ESRD
over time, for all and in different sociodemographic groups, using Cochane-Armitage tests
for trends. We employed univariable analyses (Chi squared tests for categorical variables
and t-tests for continuous variables) to identify factors associated with receipt of an ESA at
ESRD onset among LN-associated ESRD patients. Multiple imputation analyses were used
for missing baseline data [albumin, body mass index and eGFR]. We then developed
multivariable-adjusted logistic regression models including these variables to identify
factors independently associated with ESA receipt. Potential factors examined included
calendar year of ESRD onset, age, sex, race, Hispanic ethnicity, U.S. region of residence
(categorized by U.S. state as Northeast, Midwest, South, or West), comorbidities and type of
medical insurance and clinical laboratory values (hemoglobin, albumin, eGFR). All p values
were calculated with two-sided significance level of 0.05. Data analyses were performed
using SAS 9.2 (SAS Institute, Inc, Cary, North Carolina).
Results
From 1995 to 2008, there were 1,138,133 patients over age 18 with new onset ESRD of any
cause in the U.S. In this entire population, 29% of new ESRD patients received ESA
therapy. Within this group, we identified 12,533 individuals with incident lupus nephritis-
associated ESRD (1.0% of all patients), of whom 4,288 (34%) were currently receiving ESA
therapy. Eighty-two percent of LN-associated ESRD patients were female, mean age was
40.7 ± 15 years, and 49% were African American. There was a steady increase in the
proportion of patients with LN ESRD that received ESA therapy: 30% of patients in
1995-1998, 35% in 1999-2001, and 37% in 2002-2005 and a slight decline thereafter to 35%
in 2006-2008. This increase was observed in all racial and ethnic groups. Figure 1
demonstrates ESA use among patients with LN-associated ESRD, according to sex, race,
ethnicity and region of residence.
Baseline characteristics of patients with new onset LN-associated ESRD are shown in Table
1 according to ESA use. Compared to those not receiving ESAs, higher proportions of LN
ESRD patients receiving ESAs were white or Asian, were of normal weight (vs. overweight
or obese), were in categories of high hemoglobin and albumin levels at ESRD onset, were
employed, had private health insurance, and lived in the Northeast.
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In univariable and multivariable-adjusted models, several sociodemographic factors were
strongly associated with the odds of receiving ESAs at the onset of LN-associated ESRD
(Table 2). Men (compared to women), African Americans (compared to Whites), Hispanics
(compared to non-Hispanics), those with Medicaid or no medical insurance (compared to
private insurance), those living in any region of the US compared to Northeast, and those
who were unemployed (compared to employed) all had significantly reduced odds of
receiving ESA treatment at the onset of ESRD. Clinical factors were also strongly associated
with receipt of ESAs. Patients who were obese (compared to those of normal BMI) and
those who had low serum albumin (2.5 mg/dL or lower compared to those with albumin>2.5
mg/dl) had significantly lower odds of receiving ESAs. Patients who had hemoglobin levels
< 8.5 mg/dl (compared to those with hemoglobin levels between 8.6 to 10 mg/dl) had lower
odds of receiving ESAs, as did patients with higher eGFR at ESRD onset (≥10.0 ml/min vs.
<10 ml/min). Some comorbidities were associated with reduced odds of receiving ESAs,
including congestive heart failure and intravenous drug abuse. However, others, such as
CAD, hypertension and peripheral vascular disease were associated with increased odds of
receiving ESA therapy.
Discussion
The present study included more than 12,000 U.S. patients with incident LN-associated
ESRD, approximately 1% of the incident all-cause ESRD population, in the U.S from
1995-2008 to examine use of ESAs at ESRD onset in this population in particular. We
examined a range of clinical and sociodemographic factors to understand variation on their
use for this population. Thirty-four percent of LN patients received ESAs prior to initiating
renal replacement therapy, a slightly higher proportion than that of the entire USRDS
population. There was an increase in the use of ESAs from 1995 to 2005 and a slight drop
thereafter, as in the general US ESRD population [7]. Recommendations for ESA use among
patients with advanced chronic kidney disease are still evolving, taking into account data
from recent trials [8]. Randomized controlled trials in the past 6 years have demonstrated
increased risks of adverse cardiovascular events in individuals with high hemoglobin levels
(>12 or 13 g/dl) receiving ESAs [7,9-11]. The reduction in ESA use observed after 2005
may be explained by the publication and dissemination of these results.
In models simultaneously adjusting for multiple sociodemographic and clinical factors
among patients with new onset LN ESRD, we have found that women were more likely to
receive ESAs prior to renal replacement therapy initiation than men. African Americans
were less likely than whites and Hispanics were less likely than non-Hispanic patients to
receive ESAs. Our results are congruent with two past studies that examined
sociodemographic factors associated with ESA use in the new onset ESRD population in the
U.S. in the 1990s; African Americans were less likely than Whites and Hispanics were less
likely than non-Hispanics to receive ESAs [5,12]. This suggests that the racial and ethnic
disparities we have observed are pervasive and persistent.
We have found that patients with clinical or laboratory values indicating better health, such
as normal (vs. obese) BMI, and higher serum albumin and hemoglobin levels, also had
higher ESA use. It is not clear that this variation was clinically indicated. We have
previously demonstrated similar sociodemographic variation in the choice of initial
treatment modality for LN ESRD (peritoneal dialysis, hemodialysis and pre-emptive renal
transplant), according to clinical parameters which indicate overall superior health and
quality of medical care [5]. Just as pre-emptive renal transplant and peritoneal dialysis
appear to be limited to an advantaged group of LN ESRD patients, ESA therapy appears to
be prescribed unequally across clinical and sociodemographic strata of the population.
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Medical insurance and region of residence were also important factors in determining the
receipt of ESAs among patients with LN approaching ESRD. Individuals with Medicaid and
no medical insurance, those who were unemployed, as well as those who lived in the South,
West and Midwest regions (compared to the Northeast), all were less like to have received
ESA therapy at the time of renal replacement therapy onset. We have observed similar
patterns for variation in renal replacement therapy modalities for LN ESRD patients [5].
Physicians caring for LN patients may not be aware of the striking sociodemographic
variation in use of ESAs among patients with LN-associated ESRD. Despite one third of
patients with LN-associated ESRD receiving ESA therapy, there are currently no guidelines
for ESA use among LN patients. The 2012 Kidney Disease Improving Global Outcomes
(KDIGO) guidelines have recently recommended ESA therapy for all dialysis patients when
hemoglobin levels are between 9-10 g/dl and their use to maintain hemoglobin levels >9.0 g/
dl [7]. Recently published guidelines for the treatment of LN, however, have not addressed
ESA use [13,14]. LN patients have potential complications and comorbidities to be weighed
in the decision to use ESAs, including hypertension, increased risk of cardiovascular
disease, driven in part by systemic inflammation, and increased risk for thromboembolic
events due to inflammation and other pro-coagulant factors such as antiphospholipid
antibodies [15]. The decision to use ESA therapy for LN-associated anemia, as well as the
choice of initial modality for ESRD treatment, is likely influenced by healthcare provider
preference and by patient knowledge and preference. Moreover, ESAs are expensive, which
may influence the treating physician’s decision [16]. In the current multivariable models, we
found that patients with CAD, hypertension and peripheral vascular disease all had increased
odds of receiving ESA therapy. It is likely that providers were motivated to treat anemia
with ESAs in those with underlying atherosclerotic disease. However, in the absence of clear
guidelines or recommendations, striking sociodemographic variation in their use exists.
This is the first and only large observational study of ESA therapy among LN ESRD
patients, examining trends and factors associated with their use. Its strengths include its
large and inclusive population, and detailed clinical and sociodemographic data. The
USRDS includes clinical parameters specifically related to ESRD, but no data concerning
underlying SLE disease activity or specific previous immunosuppressive therapy
unfortunately. Additionally, no data concerning dose and duration of ESA use prior to the
onset of ESRD were available. A recent report compared the concordance between the
records from the USRDS and the records from the Department of Veteran Affairs (VA)
concerning ESA use at ESRD onset, and demonstrated under-recording of ESA use in 4% of
cases, reflecting a limitation to data accuracy [17]. The likely effect of such misclassification
is a bias towards the null; hence, our estimates of association can be considered to be
conservative. Our findings also may not be generalizable to other countries. The Dialysis
Outcomes and Practice Patterns Study (DOPPS) revealed variation in ESA use at the start of
dialysis with 50% of patients receiving them in Australia and New Zealand and 30 to 65% in
European countries [18].
Many concerns about safety of ESA use in patients with ESRD and LN-associated ESRD
remain unresolved. We have found that approximately one third of patients with ESRD
related to LN are receiving ESA treatment as ESRD onset. Those patients with better health
care access and superior clinical parameters had higher likelihoods of receiving ESAs. Until
we have a better understanding of the risks and benefits associated with their use in this
population, the sociodemographic disparities in access to these medications will likely
persist. Understanding whether and how ESAs are indicated and developing guidelines for
their use in patients with LN-associated ESRD is an important research goal.
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Figure 1.
Percentage of patients receiving ESA overt time in Patients with LN-associated ESRD.
Analysis according to: (A) Sex, (B) Race (Asian, African American and White), (C)
Ethnicity and (D) Region of residence (Midwest, NorthEast, South and West).
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Table 1
Baseline Characteristics of U.S. Patients with Lupus Nephritis associated ESRD, 1995-2008 (N=12,533).
ESA Use
N=4,288
No ESA Use
N=8,245 p value
Female, (%) 3,606 (84) 6,622 (80) <0.001
Age (years), (SD) 42.2 (14.8) 39.9 (14.9) 0.85
Race, (%)
African American 1,912 (44) 4,269 (52) <0.001
White 2,047 (48) 3,500 (42)
Asian 286 (7) 397 (5)
Native American 43 (1) 79 (1)
Ethnicity, (%)
Hispanic 637 (15) 1,394 (17) 0.003
BMI (kg/m2), (%)
 Underweight BMI<18 360 (8) 594 (7) 0.001
 18-25 1,890 (44) 3,470 (42)
 Overweight/Obesity BMI>25 2,038 (48) 4,181 (51)
Serum albumin (mg/dl), (%)
 ≤2.5 988 (23) 2,864 (35) <0.001
 2.6-3.2 1,389(32) 2,745 (33)
 ≥ 3.3 1,911(45) 2,636 (32)
Hemoglobin (mg/dl), (%)
 ≤8.5 1,132 (26) 2, 926 (36) <0.001
 8.6-10 1,445 (34) 2,734 (33)
 ≥10 1,711(40) 2,585 (31)
eGFR (ml/min), (%)
 ≤5.0 926 (22) 1,898 (23) 0.003
 5.0-10.0 2,400 (56) 4,352 (53)
 ≥10.0 962 (22) 1,995 (24)
Medical insurance type, (%)
 Private 1,438 (34) 2,266 (27) <0.001
 Medicaid 1,244 (29) 2,770 (34)
 No insurance 247 (6) 1,068 (13)
 Medicare 840 (20) 1217 (15)
Employment at ESRD onset, (%)
 Employed 984 (23) 1,477(18) <0.001
 Unemployed 3,304 (77) 6,768 (82)
U.S. region of residence, (%)
 Northeast 830 (20) 1,249 (15) <0.001
 West 817 (19) 1,573 (19)
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ESA Use
N=4,288
No ESA Use
N=8,245 p value
 South 1,723 (41) 3,721 (40)
 Midwest 857 (20) 1,572 (19)
Comorbidities, (%)
 Hypertension 3,469 (81) 6,173(74) <0.001
 Coronary artery disease 372 (9) 473(6) <0.001
 Peripheral vascular disease 176 (4) 241(3) <0.001
 Diabetes mellitus 399 (9) 724(9) 0.32
 Congestive heart failure 631 (15) 1,327(16) 0.04
 Chronic obstructive pulmonary disease 106 (2) 189(2) 0.52
 Cerebrovascular accident 251 (39) 398(5) 0.01
 Current smoking 153 (4) 342 (4) 0.11
 IV Drug abuse 17 (0.4) 78 (1) <0.001
 Cancer 81 (2) 108 (1) 0.01
*
t-test for age and Chi-squared tests for categorical variables comparing LN ESRD patients receiving vs. not receiving ESA.
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Table 2
Sociodemographic and Clinical Factors Significantly Associated with ESA use at Onset of ESRD among
12,533 U.S. Patients with LN from 1995-2008.
Univariable
OR 95% CI
Multivariable- Adjusted*
OR 95% CI
Sex
 Female 1.0 (ref.) - 1.0 (ref.) -
 Male 0.76 0.69-0.84 0.73 0.66-0.81
Age in years
 18-29 0.80 0.72-0.89 0.92 0.82-1.03
 30-39 1.0 (ref.) - 1.0 (ref) -
 40-49 1.10 0.99-1.23 1.00 0.89-1.12
 >50 1.23 1.11-1.36 0.99 0.89-1.11
Year of ESRD onset
 1995-1998 0.79 0.70-0.88 0.77 0.69-0.87
 1999-2001 0.98 0.88-1.09 0.96 0.86-1.08
 2002-2004 1.09 0.99-1.20 1.05 0.94-1.16
 2005-2008 1.0 (ref.) - 1.0 (ref) -
Medical Insurance
 Private 1.0 (ref.) - 1.0 (ref.) -
 Medicaid 0.73 0.67-0.81 0.84 0.75-0.94
 No insurance 0.38 0.33-0.44 0.45 0.38-0.53
 Medicare 1.03 0.92-1.16 1.07 0.95-1.22
Race
 White 1.0 (ref.) - 1.0 (ref) -
 African American 0.79 0.73-0.85 0.74 0.68-0.82
 Asian 1.31 1.11-1.54 1.18 0.99-1.41
 Native American 0.96 0.66-1.40 0.89 0.60-1.31
Ethnicity
 Hispanic 0.91 0.82-1.00 0.87 0.77-0.98
Region of Residence
 Northeast 1.0 (ref.) - 1.0 (ref) -
 West 0.80 0.71-0.91 0.72 0.64-0.83
 South 0.71 0.64-0.79 0.78 0.70-0.88
 Midwest 0.82 0.73-0.93 0.82 0.72-0.93
Employment at ESRD onset
 Employed 1.0 (ref.) - 1.0 (ref) -
 Unemployed 0.73 0.66-0.80 0.85 0.76-0.94
BMI (kg/m2)
 Underweight BMI<18 1.10 0.95-1.27 1.16 1.00-1.35
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Univariable
OR 95% CI
Multivariable- Adjusted*
OR 95% CI
 18-25 1.0 (ref.) - 1.0 (ref) -
 Overweight/Obesity BMI>25 0.88 0.82-0.95 0.87 0.80-0.94
Serum albumin (mg/dl)
 ≤2.5 0.70 0.64-0.77 0.73 0.66-0.81
 2.6-3.2 1.0 (ref) - 1.0 (ref) -
 >3.3 1.43 1.31-1.56 1.35 1.23-1.48
Hemoglobin (mg/dl)
 ≤8.5 0.75 0.68-0.83 0.80 0.72-0.88
 8.6-10 1.0 (ref) - 1.0 (ref) -
 >10 1.22 1.12-1.34 1.13 1.03-1.24
eGFR (ml/min)
 ≤0.0 0.88 0.80-0.97 1.00 0.90-1.10
 5.0-10.0 1.0 (ref) - 1.0 (ref) -
 >10.0 0.89 0.81-0.97 0.86 0.78-0.95
Comorbidities
 Hypertension 1.40 1.28-1.53 1.40 1.27-1.54
 Coronary artery disease 1.40 1.21-1.62 1.36 1.17-1.60
 Peripheral vascular disease 1.31 1.07-1.59 1.31 1.06-1.61
 Diabetes mellitus 0.98 0.86-1.12 1.08 0.94-1.23
 Congestive heart failure 0.85 0.76-0.94 0.88 0.79-0.99
 Chronic pulmonary obstructive disease 0.94 0.74-1.20 0.90 0.70-1.17
 Cerebrovascular accident 1.16 0.99-1.37 1.10 0.93-1.31
 Current smoking 0.83 0.68-1.00 0.83 0.67-1.02
 IV Drug abuse 0.42 0.25-0.71 0.56 0.32-0.97
 Cancer 1.28 0.96-1.72 1.22 0.90-1.66
eGFR: Estimated Glomerular Filtration Rate; ESA: Erythropoiesis-Stimulating Agent; LN: Lupus Nephritis; ESRD: End-Stage Renal Disease; OR:
Odds Ratio.
*
Multivariable analysis adjusted for all variables in the table.
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